Get the Stockscreener App
14.25
2.37%
0.33
After Hours:
14.50
0.25
+1.75%
Immunome Inc stock is traded at $14.25, with a volume of 1.03M.
It is up +2.37% in the last 24 hours and up +54.72% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$13.92
Open:
$13.92
24h Volume:
1.03M
Relative Volume:
0.87
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-4.3029
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-1.11%
1M Performance:
+54.72%
6M Performance:
+100.70%
1Y Performance:
+16.52%
1-Day Range:
$13.68
$14.48
1-Week Range:
$13.41
$14.78
52-Week Range:
$5.1501
$15.12
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
14.25 | 1.21B | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Can machine learning forecast Immunome Inc. recovery2025 Market Outlook & Stepwise Entry and Exit Trade Signals - newser.com
Reversal indicators forming on Immunome Inc. stockTrade Analysis Report & Real-Time Volume Surge Alerts - newser.com
How to build a custom watchlist for Immunome Inc.July 2025 Reactions & Safe Capital Growth Plans - newser.com
Using fundamentals and technicals on Immunome Inc.Weekly Trading Summary & Community Driven Trade Alerts - newser.com
Is it too late to sell Immunome Inc.July 2025 Update & High Yield Stock Recommendations - newser.com
How Immunome Inc. stock reacts to global recession fearsMarket Rally & Risk Managed Investment Strategies - newser.com
How moving averages guide Immunome Inc. tradingJuly 2025 Opening Moves & Consistent Income Trade Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Immunome (NASDAQ:IMNM) - MarketBeat
Is Immunome Inc. reversing from oversold territory2025 AllTime Highs & Technical Confirmation Alerts - newser.com
Immunome, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Immunome, Inc. Hits Day High with 16.4% Surge in Stock Price - Markets Mojo
Immunome (NASDAQ:IMNM) Trading Up 11.5%What's Next? - MarketBeat
Immunome, Inc. Hits Day High with Strong 7.93% Intraday Surge - Markets Mojo
Can trapped investors hope for a rebound in Immunome Inc.Short Setup & Capital Efficient Trade Techniques - newser.com
Key resistance and support levels for Immunome Inc.2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Wealth Enhancement Advisory Services LLC Purchases 1,643 Shares of Immunome, Inc. $IMNM - Defense World
How high can Immunome Inc. stock go2025 Dividend Review & Short-Term High Return Ideas - newser.com
Trend analysis for Immunome Inc. this weekMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Immunome Inc. stock chart pattern explainedIndex Update & Weekly Breakout Stock Alerts - newser.com
Assessing Immunome (IMNM) Valuation Following New Target Discovery Partnership with Infinimmune - Sahm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener
Does Immunome Inc. fit your quant trading modelPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Market reaction to Immunome Inc.’s recent newsJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 - BioSpace
Signal strength of Immunome Inc. stock in tech scanners2025 Trade Ideas & Weekly Momentum Picks - newser.com
Published on: 2025-10-03 01:11:18 - newser.com
Immunome, Inc. Hits Day High with Strong 8.09% Intraday Surge - Markets Mojo
How Market Conditions Affect Ginni Filaments Limiteds Growth StrategyCash Flow Trends & We Spotted the Next Tesla – See Inside - earlytimes.in
Is Immunome Inc a good long term investmentEconomic Indicators Overview & Access Powerful Market Insights - earlytimes.in
Voya Investment Management LLC Has $127,000 Stock Holdings in Immunome, Inc. $IMNM - Defense World
Immunome, Inc. Hits Day High with 14.13% Surge in Stock Price - Markets Mojo
Immunome, Inc. Hits Day High with 15.31% Surge in Stock Price - Markets Mojo
How institutional ownership impacts Immunome Inc. stock2025 Market Trends & Weekly Market Pulse Updates - newser.com
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):